DCF — MONROE CLINIC
Enterprise Value: $-155.1M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-155.1M
Enterprise Value
$-52.6M
PV of Cash Flows
$-102.5M
PV of Terminal Value
$-165.2M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $201.2M | $-7.8M | -4.0% | $-16.3M | $-14.8M |
| Year 2 | $207.2M | $-5.9M | -3.0% | $-14.7M | $-12.1M |
| Year 3 | $213.4M | $-4.0M | -2.0% | $-13.0M | $-9.8M |
| Year 4 | $219.8M | $-3.0M | -1.0% | $-12.3M | $-8.4M |
| Year 5 | $226.4M | $-2.5M | -1.0% | $-12.1M | $-7.5M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-155.1M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$195.3M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.043545206717930406
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5